FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176264321> ?p ?o ?g. }

• W3176264321 endingPage "394" @default.
• W3176264321 startingPage "381" @default.
• W3176264321 abstract "Regulatory changes have been enacted in the United States (US) and European Union (EU) to encourage the development of new treatments for pediatric cancer. Here, we review some of the factors that have hampered the development of pediatric cancer treatments and provide a comparison of the US and EU regulations implemented to address this clinical need. We then provide some recommendations for each stage of the oncology drug development pathway to help researchers maximize their chance of successful drug development while complying with regulations. A key recommendation is the engagement of key stakeholders such as regulatory authorities, pediatric oncologists, academic researchers, patient advocacy groups, and a Pediatric Expert Group early in the drug development process. During drug target selection, sponsors are encouraged to consult the Food and Drug Administration (FDA), European Medicines Agency (EMA), and the FDA target list, in addition to relevant US and European consortia that have been established to characterize and prioritize oncology drug targets. Sponsors also need to carefully consider the resourcing requirements for preclinical testing, which include ensuring appropriate access to the most relevant databases, clinical samples, and preclinical models (cell lines and animal models). During clinical development, sponsors can account for the pharmacodynamic (PD)/pharmacokinetic (PK) considerations specific to a pediatric population by developing pediatric formulations, selecting suitable PD endpoints, and employing sparse PK sampling or modeling/simulation of drug exposures where appropriate. Additional clinical considerations include the specific design of the clinical trial, the potential inclusion of children in adult trials, and the value of cooperative group trials.In the last few decades, great progress has been made in developing new treatments for adult cancers. However, development of new treatments for childhood cancers has been much slower. To encourage drug companies (sponsors) to develop effective treatments for childhood cancer, authorities in the United States (US) and Europe have made new rules for drug development. Under these new rules, sponsors developing drugs for specific cancers in adults have to consider whether the target of that drug also causes cancers in children. If this is the case, sponsors have to carry out clinical studies of their drug in children who have cancer that is caused by the same drug target. In this article, we describe some reasons for why drug development for childhood cancers has been slow and the rules created to address this problem in the US and Europe. We share some recommendations to help sponsors maximize their chances of developing an effective drug in children while satisfying the new rules. Specifically, sponsors need to be aware of the differences between studying drugs in adults versus children and how these influence the way the drug is tested. We make several recommendations for each stage of the development process, beginning with what is needed even before human studies begin. Finally, we highlight some issues that sponsors need to think about during drug development, from the preclinical stage (testing drugs in cells and animals) through to clinical testing in adults and pediatric patients with cancer." @default.
• W3176264321 created "2021-07-05" @default.
• W3176264321 creator A5002011167 @default.
• W3176264321 creator A5009149194 @default.
• W3176264321 creator A5018551530 @default.
• W3176264321 creator A5020665617 @default.
• W3176264321 creator A5042719910 @default.
• W3176264321 creator A5046385259 @default.
• W3176264321 creator A5087673195 @default.
• W3176264321 date "2021-06-26" @default.
• W3176264321 modified "2023-10-14" @default.
• W3176264321 title "Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations" @default.
• W3176264321 cites W1548059407 @default.
• W3176264321 cites W1571073982 @default.
• W3176264321 cites W1965853078 @default.
• W3176264321 cites W1969958843 @default.
• W3176264321 cites W2015758016 @default.
• W3176264321 cites W2018266072 @default.
• W3176264321 cites W2065493602 @default.
• W3176264321 cites W2073567145 @default.
• W3176264321 cites W2078494488 @default.
• W3176264321 cites W2097946365 @default.
• W3176264321 cites W2100905299 @default.
• W3176264321 cites W2104438003 @default.
• W3176264321 cites W2111724182 @default.
• W3176264321 cites W2142818804 @default.
• W3176264321 cites W2151116840 @default.
• W3176264321 cites W2179110505 @default.
• W3176264321 cites W2252231371 @default.
• W3176264321 cites W2280392194 @default.
• W3176264321 cites W2289668608 @default.
• W3176264321 cites W2321358810 @default.
• W3176264321 cites W2330247585 @default.
• W3176264321 cites W2332380311 @default.
• W3176264321 cites W2410714231 @default.
• W3176264321 cites W2537263217 @default.
• W3176264321 cites W2584356427 @default.
• W3176264321 cites W2593858973 @default.
• W3176264321 cites W2624016415 @default.
• W3176264321 cites W2725298133 @default.
• W3176264321 cites W2730922345 @default.
• W3176264321 cites W2758606946 @default.
• W3176264321 cites W2763464608 @default.
• W3176264321 cites W2770825793 @default.
• W3176264321 cites W2788109951 @default.
• W3176264321 cites W2789869568 @default.
• W3176264321 cites W2789924919 @default.
• W3176264321 cites W2794560540 @default.
• W3176264321 cites W2795866094 @default.
• W3176264321 cites W2800419642 @default.
• W3176264321 cites W2801233431 @default.
• W3176264321 cites W2803408569 @default.
• W3176264321 cites W2804091797 @default.
• W3176264321 cites W2806112411 @default.
• W3176264321 cites W2900804095 @default.
• W3176264321 cites W2905201854 @default.
• W3176264321 cites W2912132559 @default.
• W3176264321 cites W2915663023 @default.
• W3176264321 cites W2925533801 @default.
• W3176264321 cites W2928723028 @default.
• W3176264321 cites W2937643949 @default.
• W3176264321 cites W2946889418 @default.
• W3176264321 cites W2982618916 @default.
• W3176264321 cites W2985319425 @default.
• W3176264321 cites W2993541305 @default.
• W3176264321 cites W3001622551 @default.
• W3176264321 cites W3004812038 @default.
• W3176264321 cites W3013400215 @default.
• W3176264321 cites W3017435827 @default.
• W3176264321 cites W3031601960 @default.
• W3176264321 cites W3087657192 @default.
• W3176264321 cites W3089141494 @default.
• W3176264321 cites W347977075 @default.
• W3176264321 cites W4231033266 @default.
• W3176264321 cites W4233618372 @default.
• W3176264321 cites W833700056 @default.
• W3176264321 doi "https://doi.org/10.1007/s40272-021-00455-1" @default.
• W3176264321 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8275539" @default.
• W3176264321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34173206" @default.
• W3176264321 hasPublicationYear "2021" @default.
• W3176264321 type Work @default.
• W3176264321 sameAs 3176264321 @default.
• W3176264321 citedByCount "8" @default.
• W3176264321 countsByYear W31762643212022 @default.
• W3176264321 countsByYear W31762643212023 @default.
• W3176264321 crossrefType "journal-article" @default.
• W3176264321 hasAuthorship W3176264321A5002011167 @default.
• W3176264321 hasAuthorship W3176264321A5009149194 @default.
• W3176264321 hasAuthorship W3176264321A5018551530 @default.
• W3176264321 hasAuthorship W3176264321A5020665617 @default.
• W3176264321 hasAuthorship W3176264321A5042719910 @default.
• W3176264321 hasAuthorship W3176264321A5046385259 @default.
• W3176264321 hasAuthorship W3176264321A5087673195 @default.
• W3176264321 hasBestOaLocation W31762643211 @default.
• W3176264321 hasConcept C105639569 @default.
• W3176264321 hasConcept C108170787 @default.
• W3176264321 hasConcept C111472728 @default.
• W3176264321 hasConcept C121608353 @default.

• next